Design and Synthesis of Brain Penetrant Trypanocidal N-Myristoyltransferase Inhibitors

Tracy Bayliss; David Robinson; Victoria Smith; Stephen Brand; Stuart McElroy; Leah Torrie; Chidochangu Mpamhanga; Suzanne Norval; Laste Stojanovski; Ruth Brenk; Julie Frearson; Kevin Read; Ian Gilbert; Paul Wyatt

doi:10.1021/acs.jmedchem.7b01255

Design and Synthesis of Brain Penetrant Trypanocidal N-Myristoyltransferase Inhibitors

Tracy Bayliss, David Robinson, Victoria Smith, Stephen Brand, Stuart McElroy, Leah Torrie, Chidochangu Mpamhanga, Suzanne Norval, Laste Stojanovski, Ruth Brenk, Julie Frearson, Kevin Read, Ian Gilbert, Paul Wyatt (Lead / Corresponding author)

Research output: Contribution to journal › Article › peer-review

18 Citations (Scopus)

400 Downloads (Pure)

Abstract

N-Myristoyltransferase (NMT) represents a promising drug target within the parasitic protozoa Trpanosoma brucei (T. brucei), the causative agent for human African trypanosomiasis (HAT) or sleeping sickness. We have previously validated T. brucei NMT as a promising druggable target for the treatment of HAT in both stage 1 and 2 of the disease. We report on the use of the previously reported DDD85646 (1) as a start point for the design of a class of potent, brain penetrant inhibitors of T. brucei NMT.

Original language	English
Pages (from-to)	9790-9806
Number of pages	17
Journal	Journal of Medicinal Chemistry
Volume	60
Issue number	23
Early online date	10 Nov 2017
DOIs	https://doi.org/10.1021/acs.jmedchem.7b01255
Publication status	Published - 14 Dec 2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1021/acs.jmedchem.7b01255Licence: CC BY

Final published versionFinal published version, 5.65 MBLicence: CC BY

Cite this

@article{1d085d182aca453ab673da9a4de76220,

title = "Design and Synthesis of Brain Penetrant Trypanocidal N-Myristoyltransferase Inhibitors",

abstract = "N-Myristoyltransferase (NMT) represents a promising drug target within the parasitic protozoa Trpanosoma brucei (T. brucei), the causative agent for human African trypanosomiasis (HAT) or sleeping sickness. We have previously validated T. brucei NMT as a promising druggable target for the treatment of HAT in both stage 1 and 2 of the disease. We report on the use of the previously reported DDD85646 (1) as a start point for the design of a class of potent, brain penetrant inhibitors of T. brucei NMT.",

author = "Tracy Bayliss and David Robinson and Victoria Smith and Stephen Brand and Stuart McElroy and Leah Torrie and Chidochangu Mpamhanga and Suzanne Norval and Laste Stojanovski and Ruth Brenk and Julie Frearson and Kevin Read and Ian Gilbert and Paul Wyatt",

note = "Funding for this work was provided by the Wellcome Trust (Grant Ref. WT077705 and Strategic Award WT083481).",

year = "2017",

month = dec,

day = "14",

doi = "10.1021/acs.jmedchem.7b01255",

language = "English",

volume = "60",

pages = "9790--9806",

journal = "Journal of Medicinal Chemistry",

issn = "0022-2623",

publisher = "American Chemical Society",

number = "23",

}

TY - JOUR

T1 - Design and Synthesis of Brain Penetrant Trypanocidal N-Myristoyltransferase Inhibitors

AU - Bayliss, Tracy

AU - Robinson, David

AU - Smith, Victoria

AU - Brand, Stephen

AU - McElroy, Stuart

AU - Torrie, Leah

AU - Mpamhanga, Chidochangu

AU - Norval, Suzanne

AU - Stojanovski, Laste

AU - Brenk, Ruth

AU - Frearson, Julie

AU - Read, Kevin

AU - Gilbert, Ian

AU - Wyatt, Paul

N1 - Funding for this work was provided by the Wellcome Trust (Grant Ref. WT077705 and Strategic Award WT083481).

PY - 2017/12/14

Y1 - 2017/12/14

N2 - N-Myristoyltransferase (NMT) represents a promising drug target within the parasitic protozoa Trpanosoma brucei (T. brucei), the causative agent for human African trypanosomiasis (HAT) or sleeping sickness. We have previously validated T. brucei NMT as a promising druggable target for the treatment of HAT in both stage 1 and 2 of the disease. We report on the use of the previously reported DDD85646 (1) as a start point for the design of a class of potent, brain penetrant inhibitors of T. brucei NMT.

AB - N-Myristoyltransferase (NMT) represents a promising drug target within the parasitic protozoa Trpanosoma brucei (T. brucei), the causative agent for human African trypanosomiasis (HAT) or sleeping sickness. We have previously validated T. brucei NMT as a promising druggable target for the treatment of HAT in both stage 1 and 2 of the disease. We report on the use of the previously reported DDD85646 (1) as a start point for the design of a class of potent, brain penetrant inhibitors of T. brucei NMT.

U2 - 10.1021/acs.jmedchem.7b01255

DO - 10.1021/acs.jmedchem.7b01255

M3 - Article

C2 - 29125744

SN - 0022-2623

VL - 60

SP - 9790

EP - 9806

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

IS - 23

ER -

Design and Synthesis of Brain Penetrant Trypanocidal N-Myristoyltransferase Inhibitors

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this